Goodwill Pharma enters the Austrian pharmaceutical market
Goodwill Pharma Plc. plays a significant role in the pharmaceutical and therapeutic product markets in Central and Eastern Europe, primarily in Hungary, Serbia, and Poland. Additionally, it is present in Kosovo, Bosnia and Herzegovina, Macedonia, Slovakia, the Czech Republic, and Romania.
We are proud to announce that on September 17, 2024, Goodwill Pharma expanded its more than 10-year collaboration with its business partner, HENNIG ARZNEIMITTEL GmbH & Co. KG, based in Germany. Under the expanded cooperation agreement, from January 1, 2025, the company’s subsidiary, established in Austria, will exclusively handle the distribution and promotion of ARLEVERT® prescription medications in Austria. By founding its Austrian subsidiary and securing this new agreement, Goodwill Pharma enters the Austrian pharmaceutical market, enabling it to respond more swiftly to market changes and new business opportunities, further strengthening the company’s competitiveness in the regional pharmaceutical industry.
Goodwill Pharma’s mission is to deliver its products to as many people as possible to improve their quality of life. The advantages offered by its subsidiaries increase the range and accessibility of medications available to patients, while providing locally tailored solutions to meet patient needs.
The newly established Austrian subsidiary is an important milestone in the company’s expansion strategy. With this step, Goodwill Pharma will have direct access to the Austrian market, strengthening its presence in Central Europe and providing long-term sustainable growth opportunities for the company.
